Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Equillium, Inc. EQ
$0.55
-$0.02 (-4.21%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
20304319.00000000
-
week52high
3.20
-
week52low
0.48
-
Revenue
15759000
-
P/E TTM
0
-
Beta
1.20000000
-
EPS
-1.78000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 24 мар 2022 г. |
| SVB Leerink | Outperform | Outperform | 05 янв 2022 г. |
| Cantor Fitzgerald | Overweight | 15 сент 2021 г. | |
| JonesTrading | Buy | 03 мар 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 30 ноя 2020 г. |
| SVB Leerink | Outperform | Outperform | 08 сент 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 27 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| BRADBURY DANIEL | A | 50000 | 50000 | 03 янв 2023 г. |
| Connelly Stephen | A | 175000 | 175000 | 03 янв 2023 г. |
| Keyes Jason A | A | 175000 | 175000 | 03 янв 2023 г. |
| Rothman Joel | A | 175000 | 175000 | 03 янв 2023 г. |
| Zedelmayer Christine | A | 175000 | 175000 | 03 янв 2023 г. |
| Steel Bruce D. | A | 410000 | 410000 | 03 янв 2023 г. |
| Keyes Jason A | A | 35108 | 4444 | 09 дек 2022 г. |
| Rothman Joel | A | 34346 | 3821 | 09 дек 2022 г. |
| Keyes Jason A | D | 77720 | 7000 | 29 авг 2022 г. |
| Rothman Joel | A | 30525 | 6244 | 10 июн 2022 г. |
Новостная лента
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 19:02
Equillium, Inc. (EQ) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.45 per share a year ago.
Equillium to Present at Two Upcoming Investor Conferences
Business Wire
08 ноя 2022 г. в 08:00
LA JOLLA, Calif.
Why Is Equillium (EQ) Stock Soaring 20% Today?
InvestorPlace
27 сент 2022 г. в 14:20
Clinical-stage biotechnology firm Equillium (NASDAQ: EQ ), which focuses on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, released encouraging clinical data regarding itolizumab. A monoclonal antibody, itolizumab aims to provide positive outcomes for patients suffering from lupus nephritis (or LN).
Equillium's stock is up 12% after sharing early data about its investigational lupus treatment
Market Watch
27 сент 2022 г. в 08:15
Shares of Equillium Inc. EQ, -3.98% gained 12.9% in premarket trading on Tuesday after the company shared a batch of interim data from an early stage trial evaluating its experimental treatment in 13 people with lupus nephritis. Equillium said 83% of the participants enrolled in the study achieved complete or partial response, and about two-thirds had a 80% reduction in urine protein creatinine ratio by week 28.
Equillium to Present at Two Upcoming Investor Conferences
Business Wire
31 авг 2022 г. в 08:00
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the Wells Fargo Healthcare Conference and a corporate presentation at the H.C. Wainwright Annual Global Investment Conference. Management will provide a high-level overview of the company, clini